Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Eur Heart J Cardiovasc Imaging ; 17(1): 51-8, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25976347

RESUMO

AIMS: Neovascularization is closely associated with plaque progression in non-heart transplantation subjects; on the other hand, cardiac allograft vasculopathy causes unfavourable outcomes. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) can provide microscopic assessment in vivo. The aim of this study was to investigate the impact of neovascularization on intimal proliferation. METHODS AND RESULTS: Both IVUS and OCT were attempted in 45 consecutive patients during annual catheterization after heart transplantation. There were 115 vessels [28 vessels were catheterized within 8 weeks of heart transplantation (baseline)]. IVUS analysis assessed vessel, luminal, and intimal (vessel-lumen) volume using Simpson's method. Qualitative parameters including microchannel were assessed by OCT. A microchannel was defined as a no-signal tubuloluminal structure with a sharply delineated border considered to represent neovascularization. Microchannel was observed more often in patient who had their heart transplant more than a year prior to the imaging, compared with shorter periods (39.1 vs. 10.7%, P = 0.023). All microchannels were seen in thickness >0.5 mm, and intimal volume index (mm(3)/mm) correlated with frequency of microchannel (r = 0.54, P = 0.04). The risks for microchannels were donor age [odds ratio (OR) 1.11; 95% confidence interval (CI) 1.03-1.22; P = 0.007], cytomegalovirus infection (OR 16.21; 95% CI 1.79-220.09; P = 0.012), diabetes (OR 9.5; 95% CI 1.21-116.10; P = 0.032), LDL-cholesterol (OR 1.07; 95% CI 1.01-1.13; P = 0.010), and intimal volume (OR 2.47; 95% CI 1.13-6.36; P = 0.023). CONCLUSION: OCT-identified microchannels increased sharply within the first year and were correlated with intimal volume and coronary risks. This suggests that neovascularization may play an important role in the progression of cardiac allograft vasculopathy.


Assuntos
Rejeição de Enxerto/prevenção & controle , Cardiopatias/diagnóstico , Transplante de Coração , Imunossupressores/uso terapêutico , Neovascularização Patológica/diagnóstico , Tomografia de Coerência Óptica , Túnica Íntima/diagnóstico por imagem , Ultrassonografia de Intervenção/métodos , Adulto , Aloenxertos , Doença das Coronárias/diagnóstico , Feminino , Seguimentos , Cardiopatias/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Sensibilidade e Especificidade , Resultado do Tratamento
3.
Circ J ; 79(5): 1037-43, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25740501

RESUMO

BACKGROUND: Feasibility and early results of transfemoral aortic valve implantation using the ACURATE neo/TF(TM)self-expanding stent are reported. METHODS AND RESULTS: The study group of 15 patients (mean age 83.3±6.0) was enrolled with a mean EuroSCORE and STS score of 21.9±11.6% and 7.5±3.1%, respectively. Clinical and echocardiographic evaluations were performed at baseline, discharge, 30 days and 6 months. The primary endpoint was all-cause mortality at 30 days. Transcatheter aortic valve implantation (TAVI) using the ACURATE neo/TF device was successful in 14 patients; 1 patient underwent valve-in-valve implantation because the prosthetic valve embolized during withdrawal of the delivery system. Conversion to surgery, coronary obstruction, peri-operative stroke, and pacemaker implantation did not occur at 30 days. Mean transvalvular gradients at discharge significantly decreased from 44.2±10.5 mmHg (preprocedural) to 7.7±3.1 mmHg (P<0.0001) and effective orifice area significantly increased from 0.77±0.12 to 1.69±0.25 cm(2)(P<0.0001). None or trace paravalvular leak was revealed in 50.0%, and no patient exhibited moderate or higher paravalvular leak. The overall mortality at 30 days and 6 months was 0% and 6.7%, respectively. CONCLUSIONS: A new self-expanding TF TAVI device, ACURATE neo/TF, is safe and effective in the treatment of severe aortic stenosis in elderly patients at high risk for surgery.


Assuntos
Estenose da Valva Aórtica/cirurgia , Valva Aórtica/cirurgia , Implante de Prótese de Valva Cardíaca/instrumentação , Implante de Prótese de Valva Cardíaca/métodos , Próteses Valvulares Cardíacas , Idoso , Idoso de 80 Anos ou mais , Valva Aórtica/fisiopatologia , Estenose da Valva Aórtica/fisiopatologia , Feminino , Seguimentos , Humanos , Masculino
4.
J Card Surg ; 28(4): 373-9, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23879340

RESUMO

BACKGROUND: Even mild paravalvular leakage (PVL) after transcatheter aortic valve replacement (TAVR) is associated with increased late mortality. Electrocardiogram-gated multi-slice computed tomography (MSCT) enables detailed aortic annulus assessment. We describe the impact of MSCT for PVL following TAVR. METHODS: Congruence between the prosthesis and annulus diameters affects PVL; therefore, we calculated the OverSized AortiC Annular ratio (OSACA ratio) and OSACA (transesophageal echocardiography, TEE) ratio as prosthesis diameter/annulus diameter on MSCT or TEE, respectively, and compared their relationship with PVL ≤ trace following TAVR. RESULTS: Of 36 consecutive patients undergoing TAVR (Group A), the occurrence of PVL ≤ trace (33.3%) was significantly related to the OSACA ratio (p = 0.00020). In receiver-operating characteristics analysis, the cutoff value of 1.03 for the OSACA ratio had the highest sum of sensitivity (75.0%) and specificity (91.7%; AUC = 0.87) with significantly higher discriminatory performance for PVL as compared to the OSACA (TEE) ratio (AUC = 0.69, p = 0.028). In nine consecutive patients (Group B) undergoing TAVR based on guidelines formulated from our experience with Group A, PVL ≤ trace was significantly more frequent (88.9%) than that in Group A (p = 0.0060). CONCLUSIONS: The OSACA ratio has a significantly higher discriminatory performance for PVL ≤ trace than the OSACA (TEE) ratio, and aortic annular measurement from MSCT is more accurate than that from TEE.


Assuntos
Valva Aórtica/diagnóstico por imagem , Valva Aórtica/patologia , Eletrocardiografia/métodos , Implante de Prótese de Valva Cardíaca/métodos , Próteses Valvulares Cardíacas , Tomografia Computadorizada Multidetectores/métodos , Complicações Pós-Operatórias , Desenho de Prótese/efeitos adversos , Desenho de Prótese/métodos , Falha de Prótese/etiologia , Ajuste de Prótese/efeitos adversos , Ajuste de Prótese/métodos , Idoso , Idoso de 80 Anos ou mais , Ecocardiografia Transesofagiana , Feminino , Humanos , Masculino , Estudos Retrospectivos
5.
J Cardiol Cases ; 7(6): e155-e157, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30533150

RESUMO

A 45-year-old male who had suffered from refractory non-ischemic heart failure treated with a left ventricular assist device received heart transplantation in February 2008. He underwent coronary angiography (CAG) and intravascular ultrasound (IVUS) at 3 months, and 1, 2, and 3 years after surgery. At 3 months, neither significant stenosis on CAG nor plaque on 3 coronary arteries, as assessed by IVUS were observed. However, focal eccentric plaque on proximal left anterior descending artery has developed up to 2 years, despite the fact that risk factors for cardiac allograft vasculopathy were well controlled. At 2 years, everolimus 2.5 mg/day was added to the patient's existing regimen consisting of corticosteroids, mycophenolate mofetil, and cyclosporine. Then mycophenolate mofetil was withdrawn. At 3 years, concomitant with plaque regression, a decreased plaque volume index, enlarged lumen volume index, and increased minimum lumen area were observed. We experienced a case with plaque regression associated with everolimus administration. Further investigations are needed to explore the mechanism of plaque regression associated with everolimus, as well as to confirm our observation in randomized controlled trials for patients after heart transplantation. .

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA